Korro Bio, Inc. Operating Expenses
Korro Bio, Inc. (KRRO) reported Operating Expenses of $20.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Korro Bio, Inc. operating expenses for the quarter ending 2026-06-30 was $20.11M, a 29.84% decline year-over-year.
- Korro Bio, Inc. operating expenses for the quarter ending 2026-03-31 was $20.44M, a 25.88% decline year-over-year.
- Korro Bio, Inc. operating expenses for the quarter ending 2025-12-31 was $51.69M, a 104.21% increase year-over-year.
- Korro Bio, Inc. operating expenses for the quarter ending 2025-09-30 was $20.33M, a 12.73% decline year-over-year.
- Korro Bio, Inc. operating expenses for fiscal 2025 was $128.25M, a 36.17% increase from fiscal 2024.
- Korro Bio, Inc. operating expenses for fiscal 2024 was $94.18M, a 11.41% increase from fiscal 2023.
- Korro Bio, Inc. operating expenses for fiscal 2023 was $84.53M, a 43.28% increase from fiscal 2022.
- Korro Bio, Inc. operating expenses for fiscal 2022 was $59.00M, a 39.86% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.11M 10-Q · filed 2026-08-06 | $40.55M 10-Q · filed 2026-08-06 | $92.23M derived: sum of 3 quarters · filed 2026-08-06 | $112.56M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $20.44M 10-Q · filed 2026-05-07 | $72.12M derived: sum of 2 quarters · filed 2026-05-07 | $92.45M derived: sum of 3 quarters · filed 2026-05-07 | $121.11M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $51.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $72.02M derived: sum of 2 quarters · filed 2026-03-12 | $100.68M derived: sum of 3 quarters · filed 2026-08-06 | $128.25M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $20.33M 10-Q · filed 2025-11-12 | $48.99M derived: sum of 2 quarters · filed 2026-08-06 | $76.56M 10-Q · filed 2025-11-12 | $101.87M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $28.66M 10-Q · filed 2026-08-06 | $56.23M 10-Q · filed 2026-08-06 | $81.54M derived: sum of 3 quarters · filed 2026-08-06 | $104.83M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $27.57M 10-Q · filed 2026-05-07 | $52.88M derived: sum of 2 quarters · filed 2026-05-07 | $76.17M derived: sum of 3 quarters · filed 2026-05-07 | $100.30M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $25.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $48.60M derived: sum of 2 quarters · filed 2026-03-12 | $72.73M derived: sum of 3 quarters · filed 2026-03-12 | $94.18M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $23.29M 10-Q · filed 2025-11-12 | $47.42M derived: sum of 2 quarters · filed 2025-11-12 | $68.87M 10-Q · filed 2025-11-12 | $95.76M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $24.13M 10-Q · filed 2025-08-12 | $45.58M 10-Q · filed 2025-08-12 | $72.47M derived: sum of 3 quarters · filed 2025-08-12 | $91.62M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $21.45M 10-Q · filed 2025-05-07 | $48.35M derived: sum of 2 quarters · filed 2025-05-07 | $67.49M derived: sum of 3 quarters · filed 2025-05-07 | $85.90M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $26.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $46.04M derived: sum of 2 quarters · filed 2025-03-18 | $64.45M derived: sum of 3 quarters · filed 2025-03-18 | $84.53M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | $19.15M 10-Q · filed 2024-11-12 | $12.66M 10-Q · filed 2023-11-02 | $37.56M derived: sum of 2 quarters · filed 2024-11-12 | $57.64M 10-Q · filed 2024-11-12 | $45.01M 10-Q · filed 2023-11-02 | $51.83M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $18.41M 10-Q · filed 2024-08-13 | $11.83M 10-Q · filed 2023-08-10 | $38.49M 10-Q · filed 2024-08-13 | $32.34M 10-Q · filed 2023-08-10 | $32.69M derived: sum of 3 quarters · filed 2024-08-13 | $52.96M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $20.09M 10-Q · filed 2024-05-14 | $20.51M 10-Q · filed 2023-05-12 | $14.28M derived: sum of 2 quarters · filed 2024-05-14 | $34.55M derived: sum of 3 quarters · filed 2024-05-14 | $55.83M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $14.47M derived: sum of 2 quarters · filed 2024-03-26 | $35.74M derived: sum of 3 quarters · filed 2024-03-26 | $59.00M 10-K · filed 2024-03-26 | $83.00M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $20.27M 10-Q · filed 2023-11-02 | $41.55M derived: sum of 2 quarters · filed 2023-11-02 | $64.81M 10-Q · filed 2023-11-02 | $86.17M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $21.27M 10-Q · filed 2023-08-10 | $44.53M 10-Q · filed 2023-08-10 | $65.89M derived: sum of 3 quarters · filed 2023-08-10 | $90.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $23.26M 10-Q · filed 2023-05-12 | $44.62M derived: sum of 2 quarters · filed 2023-05-12 | $69.61M derived: sum of 3 quarters · filed 2023-05-12 | $96.51M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $21.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $46.35M derived: sum of 2 quarters · filed 2023-03-10 | $73.25M derived: sum of 3 quarters · filed 2023-03-10 | $98.10M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | $24.99M 10-Q · filed 2022-11-08 | $51.89M derived: sum of 2 quarters · filed 2022-11-08 | $76.74M 10-Q · filed 2022-11-08 | $96.97M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $26.90M 10-Q · filed 2022-08-09 | $51.75M 10-Q · filed 2022-08-09 | $71.98M derived: sum of 3 quarters · filed 2022-08-09 | $88.64M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $24.85M 10-Q · filed 2022-05-04 | $45.08M derived: sum of 2 quarters · filed 2022-05-04 | $61.74M derived: sum of 3 quarters · filed 2022-05-04 | $76.47M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $20.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $36.89M derived: sum of 2 quarters · filed 2022-03-15 | $51.62M derived: sum of 3 quarters · filed 2022-03-15 | $64.53M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $16.66M 10-Q · filed 2021-11-15 | $31.39M derived: sum of 2 quarters · filed 2021-11-15 | $44.31M 10-Q · filed 2021-11-15 | $55.50M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $14.72M 10-Q · filed 2021-08-12 | $27.64M 10-Q · filed 2021-08-12 | $38.84M derived: sum of 3 quarters · filed 2021-08-12 | $64.33M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $12.92M 10-Q · filed 2021-05-13 | $24.12M derived: sum of 2 quarters · filed 2021-05-13 | $49.61M derived: sum of 3 quarters · filed 2021-05-13 | $56.63M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $36.69M derived: sum of 2 quarters · filed 2021-03-29 | $43.71M derived: sum of 3 quarters · filed 2021-03-29 | $49.62M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $25.49M 10-Q · filed 2020-11-16 | $32.51M derived: sum of 2 quarters · filed 2020-11-16 | $38.42M 10-Q · filed 2020-11-16 | $43.75M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $7.02M 10-Q · filed 2020-08-12 | $12.94M 10-Q · filed 2020-08-12 | $18.26M derived: sum of 3 quarters · filed 2020-08-12 | $23.32M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | $5.92M 10-Q · filed 2020-05-14 | $11.24M derived: sum of 2 quarters · filed 2020-05-14 | $16.30M derived: sum of 3 quarters · filed 2020-05-14 | |||||
| 2018-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $10.38M derived: sum of 2 quarters · filed 2020-03-26 | $18.94M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | $5.06M 10-Q · filed 2019-11-18 | $13.62M 10-Q · filed 2019-11-18 | ||||||
| 2017-12-31 | $16.31M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |